Morgan, C; Knight, C; Lunt, M; Black, CM; Silman, AJ; (2003) Predictors of end stage lung disease in a cohort of patients with scleroderma. Annals of the Rheumatic Diseases , 62 (2) 146 - 150.
Full text not available from this repository.
OBJECTIVES: To estimate the incidence of severe lung disease in patients with scleroderma and identify the combination(s) of features present at first assessment which would be useful to predict future risk of severe lung disease. METHODS: Data were analysed on 561 patients with disease onset occurring on or after 1 January 1982 and disease duration of less than five years before the first assessment. Detailed clinical and laboratory assessments were undertaken at the initial visit. End stage lung disease was defined as pulmonary hypertension requiring continuous ambulatory iloprost, or pulmonary fibrosis requiring continuous oxygen, or death from a scleroderma related lung disease. Patient status was determined at 31 December 1997. The best subset of predictors was identified by Cox regression analysis. RESULTS: In all, 24 patients reached end stage lung disease. The cumulative incidences were 4%, 6%, and 12% at five, seven, and 14 years respectively. As expected, the lung function tests at baseline, including being in the lowest third of either diffusing lung capacity (hazard ratio (HR) = 18.2, 95% confidence interval (CI) 3.5 to 93.8) or of forced vital capacity (HR=4.1, 95% CI 1.1 to 15.2), were highly significant predictors of end stage lung disease. Interestingly, apart from the presence of proteinuria, none of the other baseline variables, including the extent of skin disease and serological markers, were predictive of severe lung disease. CONCLUSION: End stage lung disease was infrequent in this large cohort, but the cumulative incidence increased importantly with time. The risk can be predicted from baseline assessment of pulmonary function. In particular, those with normal pulmonary function at baseline are at very low risk
|Title:||Predictors of end stage lung disease in a cohort of patients with scleroderma|
|Additional information:||DA - 20030114 IS - 0003-4967 LA - eng PT - Journal Article RN - 0 (Antibodies, Antinuclear) RN - 0 (Biological Markers) SB - IM|
|Keywords:||adolescent, adult, Aged, analysis, antibodies, Antibodies, Antinuclear, Antibody, As, assessment, Biological Markers, Blood, CAPACITY, clinical, COHORT, complications, confidence, continuous, DEATH, December, disease, Disease Progression, DURATION, etiology, EXTENT, FEATURES, Female, Fibrosis, Follow-Up Studies, function, function test, future, Hypertension, Hypertension, Pulmonary, IM, Incidence, January, LA, Laboratories, laboratory, LESS, Low, Lung, Lung Function, LUNG-DISEASE, LUNG-FUNCTION, Male, MARKER, Markers, Methods, Middle Aged, ONSET, Other, Oxygen, Patient, patients, physiopathology, PREDICTORS, Prognosis, Prospective Studies, Proteinuria, pulmonary, Pulmonary Fibrosis, PULMONARY HYPERTENSION, PULMONARY-FUNCTION, RATIO, REGRESSION, Regression Analysis, Result, Risk, Risk Factors, SCLERODERMA, Scleroderma, Systemic, Sex Factors, Skin, Support, Non-U.S.Gov't, TIME, variable, VARIABLES, Vital Capacity|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Medicine (Division of)|
Archive Staff Only: edit this record